IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3006
Positioning
Market Dominance
Services
Business Services
$399M
William J. Febbo
OptimizeRx Corporation provides various solutions to life sciences organizations, healthcare providers, and patients. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies.
Headcount
100
HQ Base
Pending Verification
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = OPRX ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$YALA Yalla Group Ltd | 75 | 89 | 99 | 80 | - | - | 21.3% | 18.6% | 64.5% | 35.7% | 39.5% | 6.5% | 0.0% | 0.0x | $644M | VS | |
$GRVY GRAVITY Co., Ltd. | 75 | 82 | 96 | 71 | - | - | 15.4% | 12.6% | 38.7% | 17.1% | 17.0% | -39.7% | 0.0% | 0.0x | $439M | VS | |
$ISSC INNOVATIVE SOLUTIONS & SUPPORT INC | 73 | 81 | 88 | 94 | 25.0x | 14.1x | 28.1% | 16.8% | 48.1% | 23.8% | 18.5% | 78.6% | 0.0% | 37.0x | $220M | VS | |
$AER AerCap Holdings N.V. | 72 | 60 | 87 | 84 | - | - | 12.4% | 2.9% | 100.0% | 28.2% | 26.2% | 5.5% | 0.8% | 264.0x | $19.4B | VS | |
$HCSG HEALTHCARE SERVICES GROUP INC | 72 | 74 | 88 | 88 | 7.1x | 6.1x | 28.9% | 20.8% | 20.8% | 9.9% | 9.3% | 8.5% | 0.0% | 1.0x | $1.2B | VS | |
$LQDT LIQUIDITY SERVICES INC | 72 | 90 | 88 | 68 | 24.9x | 14.3x | 14.6% | 7.8% | 43.8% | 7.4% | 5.9% | 31.2% | 0.0% | 0.0x | $857M | VS | |
$TRTNpA Triton International Ltd | 71 | 70 | 89 | 70 | - | 1.7x | 18.0% | 4.6% | 97.3% | 52.2% | 32.7% | -3.4% | 0.0% | 271.0x | $8.0B | VS | |
$EDU New Oriental Education & Technology Group Inc. | 71 | 83 | 52 | 77 | - | - | 9.4% | 4.9% | 55.5% | 8.7% | 7.7% | 13.6% | 1.3% | 7.0x | $78.0B | VS | |
$NTES NetEase, Inc. | 71 | 88 | 93 | 68 | - | - | 22.1% | 15.6% | 62.5% | 28.1% | 28.7% | -1.0% | 2.8% | 9.0x | $56.6B | VS | |
$UTI UNIVERSAL TECHNICAL INSTITUTE INC | 70 | 86 | 86 | 72 | 43.2x | 16.0x | 21.4% | 8.0% | 100.0% | 10.0% | 7.5% | 14.1% | 0.0% | 27.0x | $1.8B | VS | |
$OPRX OptimizeRx Corp | 44 | 50 | 52 | 53 | 184.3x | 14.5x | -7.4% | -5.3% | 63.7% | -7.8% | -11.2% | 38.6% | 0.0% | 24.0x | $399M | ||
| SECTOR BENCH | - | - | - | - | - | 23.7x | 11.7x | 5.3% | 1.9% | 59.6% | 3.5% | 2.3% | 7.8% | 0.0% | 0.3x | - | REF |
OptimizeRx Corp (OPRX) receives a "Reduce" rating with a composite score of 43.8/100. It ranks #3006 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Average quality profile
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Services sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for OPRX.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 50 | 58 | -8DRAG |
| MOMENTUM | 53 | 54 | -1NEUTRAL |
| VALUATION | 52 | 55 | -3NEUTRAL |
| INVESTMENT | 24 | 13 | +11ALPHA |
| STABILITY | 30 | 21 | +9ALPHA |
| SHORT INT | 31 | 18 | +13ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC 15.4% vs WACC 8.6% (spread +6.8%)
GM 64% vs sector 60%, OM -8% vs sector 4%
Capital turnover 2.81x
Rev growth 39%, 10yr history
Interest coverage 1.8x, Net debt/EBITDA 3.0x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate OptimizeRx Corp (OPRX) as a Reduce with a composite score of 43.8/100 at a current price of $7.65. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
OptimizeRx Corp holds a top-quartile position (#0 of 50) within the Services sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 43.8/100 places it at rank #3006 in our full universe.
Narrow
High
Poor
Fair Value
Gross margins of 64% signal strong pricing power.
Stable competitive position in a defensive sector.
Elevated P/E ratio of 184.3x leaves little room for execution misses.
Vulnerability to macroeconomic shocks and interest rate volatility.
OptimizeRx Corp represents a reduce based on multi-factor quantitative performance.
OptimizeRx Corp receives a Reduce rating from our analysis, with a composite score of 43.8/100 and 2 out of 5 stars, ranking #3006 out of 7,333 stocks. OPRX's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
With a quality score of 50/100, OPRX shows adequate but unremarkable business quality. The company reports a return on equity of -7.4% (sector avg: 5.3%), gross margins of 63.7% (sector avg: 59.6%), net margins of -11.2% (sector avg: 2.3%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
OPRX's value score of 52/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 184.25x, an EV/EBITDA of 14.51x, a P/B ratio of 1.25x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
OptimizeRx Corp's investment score of 24/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 38.6% vs. a sector average of 7.8% and a return on assets of -5.3% (sector: 1.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
OPRX demonstrates moderate momentum with a score of 53/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 38.6% year-over-year, while a beta of 1.37 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
OPRX's stability score of 30/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.37 and a debt-to-equity ratio of 24.00x (sector avg: 0.3x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
OptimizeRx Corp's short interest score of 31/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.37), elevated leverage (D/E: 24.00x), small-cap liquidity risk. At $399M (small-cap), OPRX carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
OptimizeRx Corp is a small-cap company in the Services sector, ranked #0 of 50 in its sector (100th percentile) and #3006 of 7,333 overall (59th percentile). Key comparisons include ROE of -7.4% trailing the 5.3% sector median and operating margins of -7.8% below the 3.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Services peers.
While OPRX currently exhibits a REDUCE profile, superior opportunities exist within the SERVICES sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Services Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (24) would have the largest impact on the composite score.
EV/EBITDA 24% ABOVE SECTOR MEDIAN
ROE 239% BELOW SECTOR MEDIAN
Gross Margin 7% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
OptimizeRx Corp (NASDAQ:OPRX) is one of the best performing micro cap stocks in 2025.
OptimizeRx (NASDAQ:OPRX) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 0 0 0 2M Ago 1 2 0 0 0 3M Ago 0 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $14.6, with a high estimate of $17.00 and a low estimate of $13.00. This current average has increased by 12.31% from the previous average price target of $13.00. Breaking Down Analyst Ratings: A Detailed Examination The analysis of recent analyst actions sheds light on the perception of OptimizeRx by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target David Grossman Stifel Maintains Buy $13.00 $13.00 Constantine Davides JMP Securities Maintains Market Outperform $15.00 - Constantine Davides JMP Securities Announces Market Outperform $15.00 - David Grossman Stifel Maintains Buy $13.00 $13.00 Sean Dodge RBC Capital Maintains Outperform $17.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', ...Full story available on Benzinga.com
Smith Micro Software, Inc. reported a Q2 loss of $0.38 per share, missing the Zacks Consensus Estimate of a loss of $0.35. The company's revenue of $5.14 million also missed estimates. The stock has lost about 62.9% since the beginning of the year.
The consensus price target hints at a 34.8% upside potential for OptimizeRx (OPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Open Text (OTEX) delivered earnings and revenue surprises of 0% and 1.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?